---
title: "健民药业集团股份有限公司 (600976.SH)"
type: "quote"
locale: "en"
url: "https://longbridge.com/en/quote/600976.SH.md"
symbol: "600976.SH"
name: "健民药业集团股份有限公司"
industry: "制药"
---

# 健民药业集团股份有限公司 (600976.SH)

| Item | Detail |
|------|--------|
| Industry | 制药 |
| Location | 沪深市场 |
| Website | [www.whjm.com](https://www.whjm.com) |

## Company Profile

公司始创于明崇祯十年 (1637 年)，原名 “叶开泰”，解放前便享有 “初清三杰”、“中国四大药号” 的美誉。1953 年，葉開泰号制药部分被改造为 “武汉市健民制药厂”,2004 年在上海证券交易所上市。公司主要从事药品的研发、制造、批发与零售业务，主要分为医药工业和医药商业两大板块。主要产品：龙牡壮骨颗粒、便通胶囊、健脾生血颗粒、括健脾生血片、小金胶囊、小儿宝泰康颗粒等;医药商业;中医诊疗。公司荣誉有中华老字号、14 年度中国制药工业百强第 45 位 2002 年质量万里行先进单位、2002 年质量万里行先进单位、2024 大健康产业星锐伙伴奖、2023 年药企 TOP50、西湖奖·医药...

## Financial Score

> *Longbridge Financial Score™ — Proprietary multi-factor rating model by [Longbridge](https://longbridge.com). This score is independently calculated by Longbridge and is not affiliated with any third-party rating agency.*
> Updated: 2026-02-20T04:30:09.000Z

**Overall: C (0.45)**

**Industry**: Pharmaceuticals

| Metric | Value |
|--------|-------|
| Industry Ranking | 142 / 222 |
| Industry Median | C |
| Industry Average | C |

- **Style**: Value - Stocks where the company's main business is in a mature stage.
- **Scale**: Small - The company's operation has a high degree of growth and volatility, making it easy to achieve high investment returns.

### Score Analysis

**Style Score**: 

#### Growth Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Revenue YoY | -20.15% |  |
| Net Profit YoY | -23.75% |  |

#### Value Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| P/B Ratio | 1.97 |  |
| Dividend Ratio | 2.72% |  |


**Size Score**: 

#### Market Cap Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Market Cap | 5.08B |  |

#### Revenue Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Revenue | 3.18B |  |


**Multi Score**: C

#### Profit Score: B

| Indicator | Value | Rating |
|-----------|-------|--------|
| ROE | 13.11% | B |
| Profit Margin | 10.28% | B |
| Gross Margin | 58.77% | B |

#### Growth Score: D

| Indicator | Value | Rating |
|-----------|-------|--------|
| Revenue YoY | -20.15% | E |
| Net Profit YoY | -23.75% | D |
| Total Assets YoY | 3.14% | C |
| Net Assets YoY | 8.06% | B |

#### Cash Score: C

| Indicator | Value | Rating |
|-----------|-------|--------|
| Cash Flow Margin | 973.21% | B |
| OCF YoY | -20.15% | E |

#### Operating Score: B

| Indicator | Value | Rating |
|-----------|-------|--------|
| Turnover | 0.74 | B |

#### Debt Score: C

| Indicator | Value | Rating |
|-----------|-------|--------|
| Gearing Ratio | 40.05% | C |


```chart-data:radar
{
  "title": "Longbridge Financial Score - 健民药业集团股份有限公司",
  "chart_type": "radar",
  "dimensions": [
    {
      "name": "Profit",
      "grade": "B",
      "indicators": [
        {
          "name": "ROE",
          "value": "13.11%",
          "rating": "B"
        },
        {
          "name": "Profit Margin",
          "value": "10.28%",
          "rating": "B"
        },
        {
          "name": "Gross Margin",
          "value": "58.77%",
          "rating": "B"
        }
      ]
    },
    {
      "name": "Growth",
      "grade": "D",
      "indicators": [
        {
          "name": "Revenue YoY",
          "value": "-20.15%",
          "rating": "E"
        },
        {
          "name": "Net Profit YoY",
          "value": "-23.75%",
          "rating": "D"
        },
        {
          "name": "Total Assets YoY",
          "value": "3.14%",
          "rating": "C"
        },
        {
          "name": "Net Assets YoY",
          "value": "8.06%",
          "rating": "B"
        }
      ]
    },
    {
      "name": "Cash",
      "grade": "C",
      "indicators": [
        {
          "name": "Cash Flow Margin",
          "value": "973.21%",
          "rating": "B"
        },
        {
          "name": "OCF YoY",
          "value": "-20.15%",
          "rating": "E"
        }
      ]
    },
    {
      "name": "Operating",
      "grade": "B",
      "indicators": [
        {
          "name": "Turnover",
          "value": "0.74",
          "rating": "B"
        }
      ]
    },
    {
      "name": "Security",
      "grade": "C",
      "indicators": [
        {
          "name": "Gearing Ratio",
          "value": "40.05%",
          "rating": "C"
        }
      ]
    }
  ]
}
```

### Peer Comparison

| Rank | Name | Profit | Growth | Operation | Security | Cash | Rating |
|------|------|--------|--------|-----------|----------|------|--------|
| 01 | 艾力斯 (SH.688578) | A | A | B | A | B | A |
| 02 | 兴齐眼药 (SZ.300573) | A | A | A | B | B | A |
| 03 | 恒瑞医药 (SH.600276) | A | B | C | A | B | B |
| 04 | 云南白药 (SZ.000538) | B | C | B | B | C | B |
| 05 | 信立泰 (SZ.002294) | B | B | C | A | B | B |

## Valuation Analysis

| Metric | Current | Industry Ranking | High | Median | Low |
|--------|---------|-----------------|------|--------|-----|
| PE (TTM) | 15.57 | 15/222 | 18.52 | 16.98 | 16.16 |
| PB | 1.97 | 70/222 | 2.58 | 2.44 | 2.14 |
| PS (TTM) | 1.60 | 21/222 | 1.92 | 1.83 | 1.68 |
| Dividend Yield | 2.72% | 31/222 | 2.62% | 2.30% | 2.20% |

## Institutional View

### Analyst Rating Distribution

> As of 2024-11-21T16:00:00.000Z

Total Analysts: **1**

| Rating | Count | Percentage |
|--------|-------|-----------|
| Buy | 1 | 100% |
| Overweight | 0 | 0% |
| Hold | 0 | 0% |
| Underweight | 0 | 0% |
| Sell | 0 | 0% |

### Target Price Forecast

| Metric | Price |
|--------|-------|
| Current Price | 33.13 |

## References

- [Company Overview](https://longbridge.com/en/quote/600976.SH/overview.md) - Shareholders, executives, business segments
- [Financials](https://longbridge.com/en/quote/600976.SH/norm.md) - Income statement, balance sheet, cash flow, distribution plan
- [Topics & Discussions](https://longbridge.com/en/quote/600976.SH/topics.md) - Community topics and discussions

---

> **Disclaimer**: This article is for reference only and does not constitute any investment advice.